UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

Journal of neuroscience research, 2011-04, Vol.89 (4), p.481-489

2011

Volltextzugriff (PDF)

Peptides originally derived from Chilobrachys jingzhao tarantula venom possess beneficial effects on pancreatic beta cell health and function

European journal of pharmacology, 2023-09, Vol.954, p.175855-175855, Article 175855

2023

Volltextzugriff (PDF)

Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential

Biochemical pharmacology, 2018-09, Vol.155, p.264-274

2018

Volltextzugriff (PDF)

Effects of an enzymatically stable C-terminal hexapseudopeptide fragment peptide of xenin-25, ψ-xenin-6, on pancreatic islet function and metabolism

Molecular and cellular endocrinology, 2019-10, Vol.496, p.110523-110523, Article 110523

2019

Volltextzugriff (PDF)

Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice

International Journal of Obesity, 2013-05, Vol.37 (5), p.678-684

2013

Volltextzugriff (PDF)

Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice

Molecular and cellular endocrinology, 2015-02, Vol.401, p.120-129

2015

Volltextzugriff (PDF)

Comparison of independent and combined effects of the neurotensin receptor agonist, JMV-449, and incretin mimetics on pancreatic islet function, glucose homeostasis and appetite control

Biochimica et biophysica acta. General subjects, 2021-08, Vol.1865 (8), p.129917-129917, Article 129917

2021

Volltextzugriff (PDF)

Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance

Diabetes, obesity & metabolism, 2010-10, Vol.12 (10), p.891-899

2010

Volltextzugriff (PDF)

A GIP/xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice

Biochemical pharmacology, 2020-01, Vol.171, p.113723-113723, Article 113723

2020

Volltextzugriff (PDF)

Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice

European journal of pharmacology, 2019-12, Vol.865, p.172733-172733, Article 172733

2019

Volltextzugriff (PDF)

Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet

International Journal of Obesity, 2010-08, Vol.34 (8), p.1341-1344

2010

Volltextzugriff (PDF)

Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice

Molecular and cellular endocrinology, 2015-09, Vol.412, p.95-103

2015

Volltextzugriff (PDF)

Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice

Molecular and cellular endocrinology, 2016-01, Vol.420, p.37-45

2016

Volltextzugriff (PDF)

A novel analogue of oxyntomodulin with improved glucose-lowering, insulinotropic and anorexigenic actions

Regulatory peptides, 2010-09, Vol.164 (1), p.33-33

2010

Volltextzugriff (PDF)

Investigating the role of the glutamyl linker on the biological efficacy of Liraglutide

Regulatory peptides, 2010-09, Vol.164 (1), p.44-45

2010

Volltextzugriff (PDF)

The glucagon-like peptide-1 agonist Liraglutide improves memory and learning in obese-diabetic mice

Regulatory peptides, 2010-09, Vol.164 (1), p.40-40

2010

Volltextzugriff (PDF)

Prolonged GIP receptor activation improves glucose homeostasis and cognitive function in high-fat fed mice

Regulatory peptides, 2010-09, Vol.164 (1), p.44-44

2010

Volltextzugriff (PDF)

Xenin: An anorectic peptide involved in insulin secretion and glucose homeostasis

Regulatory peptides, 2010-09, Vol.164 (1), p.41-41

2010

Volltextzugriff (PDF)

Daily administration of the GIP-R antagonist (Pro³)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro³)GIP

Diabetes, obesity & metabolism, 2008-04, Vol.10 (4), p.336-342

2008

Volltextzugriff (PDF)

DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2–Asp13)GIP

Cell biology international, 2003-01, Vol.27 (1), p.41-46

2003

Volltextzugriff (PDF)

Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala 8/Ala 2 with 2-aminobutyric acid

Archives of biochemistry and biophysics, 2004, Vol.428 (2), p.136-143

2004

Volltextzugriff (PDF)

Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide

Bioscience reports, 2002-10, Vol.22 (5-6), p.523-528

2002

Volltextzugriff (PDF)

Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid

Archives of biochemistry and biophysics, 2004-08, Vol.428 (2), p.136-143

2004

Volltextzugriff (PDF)

Lys 9 for Glu 9 substitution in glucagon-like peptide-1(7–36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9–36)amide and exendin (9–39)

Metabolism, clinical and experimental, 2004, Vol.53 (2), p.252-259

2004

Volltextzugriff (PDF)

Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)

Metabolism, clinical and experimental, 2004-02, Vol.53 (2), p.252-259

2004

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(26)
Dissertationen
(1)

Sprache

Englisch
(27)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Animals
(16)
Science & Technology
(16)
Life Sciences & Biomedicine
(15)
Mice
(14)
Insulin Secretion
(10)
Diabetes
(9)
Endocrinology & Metabolism
(8)
Insulin - Metabolism
(8)
Male
(8)
Hypoglycemic Agents - Pharmacology
(7)
Gip
(6)
Glp-1
(6)
Blood Glucose - Metabolism
(5)
Cell Biology
(5)
Glucagon
(5)
Insulin - Blood
(5)
Islets Of Langerhans - Metabolism
(5)
Peptide Fragments - Pharmacology
(5)
Diet, High-Fat - Adverse Effects
(4)
Glucagon-Like Peptide 1 - Analogs & Derivatives
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

Peptides originally derived from Chilobrachys jingzhao tarantula venom possess beneficial effects on pancreatic beta cell health and function

Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential

Effects of an enzymatically stable C-terminal hexapseudopeptide fragment peptide of xenin-25, ψ-xenin-6, on pancreatic islet function and metabolism

Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice

Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice

Comparison of independent and combined effects of the neurotensin receptor agonist, JMV-449, and incretin mimetics on pancreatic islet function, glucose homeostasis and appetite control

Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance

A GIP/xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice

Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice

Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet

Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice

Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice

A novel analogue of oxyntomodulin with improved glucose-lowering, insulinotropic and anorexigenic actions

Investigating the role of the glutamyl linker on the biological efficacy of Liraglutide

The glucagon-like peptide-1 agonist Liraglutide improves memory and learning in obese-diabetic mice

Prolonged GIP receptor activation improves glucose homeostasis and cognitive function in high-fat fed mice

Xenin: An anorectic peptide involved in insulin secretion and glucose homeostasis

Daily administration of the GIP-R antagonist (Pro³)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro³)GIP

DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2–Asp13)GIP

Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala 8/Ala 2 with 2-aminobutyric acid

Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide

Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid

Lys 9 for Glu 9 substitution in glucagon-like peptide-1(7–36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9–36)amide and exendin (9–39)

Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39)

Suchergebnisse filtern